Peroxisome proliferator-activated receptor alpha (PPARα), the molecular target of fibrates commonly used to treat dyslipidemia and diabetes, inhibits DNMT1 activity and abolishes methylation-mediated CDKN2A repression in CRC both in vitro and in vivo, indicating that it may be an applicable agent for epigenetic therapy of colon cancer patients [92]. Here, PPARA is linked to metabolic syndrome.